TLR7 AGONISTS Russian patent published in 2024 - IPC C07D473/32 A61K31/522 A61P35/00 A61P31/12 

FIELD: medicine; pharmaceutics.

SUBSTANCE: invention relates to TLR7 agonists and pharmaceutically acceptable salts thereof, represented by general formula I, where R¹ is -H, -OH, -OC(O)-R⁶ or -F; R² is -H or -F; R³ is independently -OH or -OC (O) -R⁷; R⁴ is -(C₁-C₈)alkyl, -(C₁-C₈)alkenyl, -(C₁-C₈)alkynyl, -(C₁-C₈)haloalkyl, -(CH₂)_n(cycloalkyl), -(CH₂)_n(aryl) or -(CH₂)_nC(O)OR⁶; R⁵ is -H, -OH or -Cl; R⁶ and R⁷ are -(C₁-C₈) alkyl; n is equal to integer 1, 2, 3 or 4; each alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl and aryl are independently optionally substituted with CN, halogen atom, (C₁-C₃)haloalkyl, aryl, OH, O-(C₁-C₃)alkyl, C(O)R⁸, S(C₁-C₈)alkyl, C(O)NOR⁸, C(O)NR⁸R⁸, C(O)NR⁸SO₂ alkyl, NR⁸R⁸, and R⁸ independently represents -H, -OH or -(C₁-C₈)alkyl. Invention also relates to compounds having a structure presented in the claim and pharmaceutically acceptable salts thereof, to a pharmaceutical composition and a method of treating diseases caused by TLR7 agonism.

EFFECT: providing TLR7 agonist compounds.

23 cl, 4 tbl, 370 ex